Originally spun out from the prestigious Institut Curie and Sorbonne University (Paris, France), PEP-Therapy is a clinical-stage company developing first-in-class peptides as targeted therapies for the treatment of aggressive cancers.

Following promising Phase Ia results, including preliminary signs of efficacy, PEP-Therapy is now performing Phase Ib trials (NCT 04733027) in both Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma (PROC and PDAC).

PEP-Therapy is strongly backed by international investors: Seventure Partners, i&i Prague, Italian Angels for Growth (IAG), Doorway, Anaxago, Magna Capital Partners (MCP), BAdGE, and Majoie family.

PEP-010, PEP-Therapy’s flagship product, in summary:
– First-in-class bifunctional targeted peptide
– MoA: triggering apoptosis by disruption of Caspase-9/PP2A interaction
– Phase Ia promising results: – Favorable safety and tolerability profiles, RP2D determined in monotherapy and in combination with paclitaxel – Promising signals of antitumor activity
– Phase Ib trials underway (NCT 04733027): multicenter (in partnership with leading clinical oncology centers: Institut Curie, Gustave Roussy)
– Focus on PROC and PDAC (Platinum-Resistant Ovarian Cancer and Pancreatic Ductal Adenocarcinoma) in combination with paclitaxel and gemcitabine
– Indication expansion potential, in solid and in liquid cancers
– Translational biomarkers development ongoing
– Spin-off from the prestigious Institut Curie and Sorbonne University. Backed by international investors.

–  Therapeutic areas: Oncology, Cancer

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2014